Trial | NCT01642667  Report issue

Title

Pharmacoinvasive Therapy With Prourokinase
The Efficacy and Safety of Pharmacoinvasive Therapy With Prourokinase for Acute ST Segment Elevation Myocardial Infarction Patients With Expected Percutaneous Coronary Intervention Related Delay

  • Phase

    Phase 2/Phase 3

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    alteplase ...

  • Study Participants

    197
The aim of this study is to elucidate the efficacy and safety of pharmacoinvasive therapy by using prourokinase (prouk), a unique fibrin-specific agent, in patients with ST-segment elevation myocardial infarction (STEMI)
Study Started
Nov 30
2008
Primary Completion
Nov 30
2009
Study Completion
Dec 31
2010
Last Update
Jul 27
2012
Estimate

Drug Prourokinase

a bolus of 1.2 million IU and an infusion of 4.8 million IU in 60 min.

Drug Placebo

primary PCI Placebo Comparator

prouk-PCI Active Comparator

Criteria 

Inclusion Criteria:

age 75 years or younger, symptom onset 6 h or less before randomization, intention to undertake primary PCI, ST-segment elevation of 2 mm or more in two anterior leads or of 1 mm or more in two inferior leads if they had ST-segment elevation, or new left bundle-branch block.

Exclusion Criteria:

expected arrival at the catheterization laboratory less than 1 h or more than 3 h after randomization, anticipated problems with vascular access, previous enrollment to other studies, and the usual contraindications to thrombolytic therapy.
No Results Posted